- Home
- APGE
as of 02-13-2026 4:00pm EST
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 4.5B | IPO Year: | 2023 |
| Target Price: | $103.33 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.20 - $84.56 | Next Earning Date: | 03-02-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -237559000.0 | FCF Growth: | N/A |
AI-Powered APGE Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Apogee Therapeutics Inc. (APGE)
Chief Medical Officer
Avg Cost/Share
$66.88
Shares
5,500
Total Value
$361,860.03
Owned After
212,747
Chief Financial Officer
Avg Cost/Share
$66.08
Shares
2,000
Total Value
$131,629.52
Owned After
183,471
Director
Avg Cost/Share
$76.30
Shares
1,750,000
Total Value
$133,525,000.00
Owned After
298,647
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$80.00
Shares
2,000
Total Value
$160,000.00
Owned After
183,471
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$74.66
Shares
6,000
Total Value
$449,145.60
Owned After
183,471
Chief Financial Officer
Avg Cost/Share
$80.00
Shares
1,500
Total Value
$120,000.00
Owned After
183,471
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Dambkowski Carl | APGE | Chief Medical Officer | Feb 4, 2026 | Sell | $66.88 | 5,500 | $361,860.03 | 212,747 | |
| Henderson Jane | APGE | Chief Financial Officer | Feb 2, 2026 | Sell | $66.08 | 2,000 | $131,629.52 | 183,471 | |
| Fairmount Funds Management LLC | APGE | Director | Jan 22, 2026 | Sell | $76.30 | 1,750,000 | $133,525,000.00 | 298,647 | |
| Henderson Jane | APGE | Chief Financial Officer | Jan 6, 2026 | Sell | $80.00 | 2,000 | $160,000.00 | 183,471 | |
| Henderson Jane | APGE | Chief Financial Officer | Jan 2, 2026 | Sell | $74.66 | 6,000 | $449,145.60 | 183,471 | |
| Henderson Jane | APGE | Chief Financial Officer | Dec 19, 2025 | Sell | $80.00 | 1,500 | $120,000.00 | 183,471 |
Compare APGE vs Leading Stocks
See how APGE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "APGE Apogee Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.